脂肪酸伸長酵素Elovl6による脂肪酸の質の制御と生活習慣病

  • 松坂 賢
    筑波大学医学医療系内分泌代謝・糖尿病内科トランスボーダー医学研究センターエネルギー代謝科学分野
  • 島野 仁
    筑波大学医学医療系内分泌代謝・糖尿病内科トランスボーダー医学研究センターエネルギー代謝科学分野

書誌事項

タイトル別名
  • Role of Fatty Acid Elongase Elovl6 in the Regulation of Fatty Acid Quality and Lifestyle-related Diseases
  • シボウサン シンチョウ コウソ Elovl6 ニ ヨル シボウサン ノ シツ ノ セイギョ ト セイカツ シュウカンビョウ

この論文をさがす

説明

<p>The increasing prevalence of obesity worldwide has become an alarming public health concern because of dramatic increases in the incidence of obesity-associated diseases, including type 2 diabetes mellitus (T2DM). Peripheral insulin resistance and impaired insulin secretion remain the core defects in T2DM. Despite significant advances in unraveling the mechanisms underlying these defects, many of the metabolic pathways and regulators involved in insulin resistance and β-cell dysfunction are not completely understood. This review proposes that manipulating the fatty acid (FA) composition by blocking ELOVL fatty acid elongase 6 (Elovl6) could protect against insulin resistance, impaired insulin secretion, and obesity-related disorders. Elovl6 is a microsomal enzyme involved in the elongation of C16 saturated and monounsaturated FAs to form C18 FAs. We have reported that mice with Elovl6 deletion are protected against obesity-induced insulin resistance or β-cell failure because the cellular FA composition is changed, even with concurrent obesity. Therefore, Elovl6 appears to be a crucial metabolic checkpoint, and limiting the expression or activity of Elovl6 could be a new therapeutic approach in the treatment of T2DM.</p>

収録刊行物

  • 薬学雑誌

    薬学雑誌 142 (5), 473-476, 2022-05-01

    公益社団法人 日本薬学会

参考文献 (9)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ